Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to ...

Aubrey Moore netted three goals and had an assist for Parsippany Hills in its 11-9 win over Morris Catholic in Parsippany. Parsippany Hills (2-6) led 6-2 at halftime against Morris Catholic.

Finnian O’Loughlin allowed no hits over five innings with three strikeouts and two walks as top-seeded Delbarton, No. 5 in the NJ.com Top 20, defeated 16th-seeded Parsippany 10-0 in the Morris ...

Shares of Gilead Sciences Inc. GILD rallied 2.24% to $106.54 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.15% ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which ...

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle civil claims that the drugmaker used speaker programs to pay kickbacks to doctors to induce them to ...

EPS: US$1.06 (up from US$3.34 loss in 1Q 2024). Our free stock report includes 2 warning signs investors should be aware of before investing in Gilead Sciences. Read for free now. Revenue missed ...

Gilead Sciences(NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. After publishing its earnings report after market close Thursday, the company saw its ...

This meant a mixed quarter for Gilead. On average, analysts were modeling $6.78 billion for revenue, but anticipating a lower per-share adjusted profit of $1.77. Annual profit guidance reduced ...

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Gilead Sciences. The Motley Fool has a disclosure policy.